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HealtH-Related Quality of life of Patients on oPiate RePlaceMent 
tHeRaPy
Adams R.
National Centre for Pharmacoeconomics, Dublin, Ireland
Objectives: To evaluate health-related quality of life (HRQOL) and contributing 
factors in individuals receiving opiate replacement therapy. MethOds: This was 
a cross-sectional study of patients attending for methadone therapy in an inner 
city drug treatment centre. EQ-5D, SF-36, SF-6D, Hospital Anxiety Depression Scale 
(HADs) were assessed, along with substance abuse via the Treatment Outcomes 
Profile (TOPs). Mean values, ranges and standard deviations were calculated and 
utility scores were derived. Analysis was performed using Spearman’s correlation 
and t-test to determine any significant correlations. Results: A total of 115 patients 
were included, 72% were male and the mean age was 35 years. 63% were HCV-PCR 
positive and 49% admitted to using drugs in the past month. 57% of patients had 
high levels of anxiety with the mean score being 11.14 (anxious). 35% were depressed 
with the mean score being 8.40 (borderline depressed). The mean EQ-5D utility 
score was 0.56 with 7% having a utility score that was worse than death. The mean 
SF-36 utility score was 0.55. The mean SF-36 physical component score was 44.25 
and the mean mental component score was 33.18. cOnclusiOns: HRQOL was 
reduced in this opiate replacement therapy cohort. HCV, gender and injecting drug 
use did not affect HRQOL but anxiety, depression and use of crack cocaine had a 
significant impact.
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dePendence in tHe PRiMaRy caRe setting in tHe united KingdoM 
(stReaM)
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Objectives: Describe the management of alcohol dependence at general practitioner 
(GP) level. MethOds: STREAM is a non-interventional, 6-month prospective study of 
adult patients undergoing targeted alcohol screening during routine consultation by 
GPs throughout England and Scotland, for whom alcohol problems were either known 
or suspected on the basis of clinical signs or patient’s report. Inclusion criteria were an 
AUDIT score > = 8 and consent. At baseline, diagnosis of dependence was made using 
the DSM-IV criteria and data were collected on socio-demographic characteristics, co-
morbidities, alcohol consumption with the timeline follow-back method, previous and 
current alcohol treatment, treatment goal (abstinence or reduction of alcohol consump-
tion). The data were analyzed descriptively. Results: A total of 218 patients screened 
positive and were included in 26 sites. A total of 79% of patients fulfilled the DSM-IV 
criteria for alcohol dependence; 74% were men, the mean age was 50 years and only 
29% were working full or part-time. 40% of patients had a history of alcohol treatment 
(almost always counseling), 20% had a history of detoxification and 9% a history of 
pharmacological treatment. At inclusion, the proportion of patients with ongoing treat-
ment for alcohol addiction was 28% and these patients were drinking in average 63 g/
day compared to 89 g/d in untreated patients. Of those patients on treatment or about 
to initiate it, alcohol reduction was more frequently the treatment goal than abstinence 
(51% vs. 45%). cOnclusiOns: Targeted screening is an effective way for GPs to identify 
patients with alcohol dependence opportunistically. Many such patients have a history 
of counseling but few have received pharmacological interventions. Only a minority of 
those with alcohol dependence have ever received any form of treatment. For the major-
ity of those in treatment, alcohol reduction is the treatment goal of choice. Consumption 
levels in patients with dependence tend to be high, irrespective of treatment status.
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Objectives: Elderly people facing dependence are exposed to the financial risk of 
long lasting care expenditures. This risk is high for people facing cognitive, func-
tional and behavioral problems. In the short-term, dependent elderly people face 
increased non-medical care expenditures. In the long-term, they face increase medi-
cal care expenditures, driven by extended hospital stays. In France, providing public 
financial assistance has been showed to improve dependent people’s access to 
non-medical care services. However, the long-term impact of public financial assis-
tance on care trajectories has not been explored yet. Our study aims at determining 
whether financial assistance on non-medical care provision decreases hospital stays 
rates. MethOds: We run Fixed Effects Poisson regression models using longitudinal 
data of 574 French patients diagnosed with Alzheimer’s disease. We use instrumen-
tal variables to reduce the presence of a potential endogeneity bias. Results: We 
find that beneficiaries of home care subsidies have a 34% lower rate of hospitaliza-
tion than non-beneficiaries. cOnclusiOns: Providing public financial assistance 
is effective to reduce hospitalizations in Alzheimer’s disease.
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Objectives: The increasing prevalence of dementia worldwide highlights the need 
for effective and individualized support systems for dementia treatment and care. 
Facing the reality of increasing internet usage as well as the large availability of 
digitalized information, there is a high potential for ehealth interventions. Therefore 
one purpose of this project is to provide a ‘Personal eHealth Knowledge Space’ (PeKS) 
toms in chronic obstructive pulmonary disease (COPD) in India. A study was 
undertaken to investigate the prevalence and risk factors of depression in the 
Indian COPD patients. MethOds: COPD was classified according to GOLD stages 
based on forced expiratory volume in one second (FEV1) in 126 stable patients. 
Depression was examined by administering the nine-item Hindi version of Patient 
Health Questionnaire-9 (PHQ-9). Linear regression model was used to examine 
association between predictor variables and risk of depression with adjustment 
of age and sex. Cronbach alpha was calculated to assess internal consistency of 
PHQ-9. Results: Patients with stable COPD (n= 126) were evaluated (73.8% male 
and 26.2% female). In the study population as whole, 33.3% patients showed mod-
erate to severe depressive symptoms whereas 20.6% patients had major depressive 
disorder on PHQ-9 Scale. Educational and occupational status, body mass index, 
FEV1, respiratory symptoms, physical impairment and dyspnea were found to be 
potential predictors of depression in COPD patients. cOnclusiOns: One-fifth of 
the patients with COPD had severe symptoms of related to depression, which was 
especially higher with severity of COPD. Hence, the patients with COPD should 
focus on management of these two conditions. Further, future studies should be 
conducted to assess the role of depression management and timely treatment of 
it in the patients with COPD.
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Objectives: To analyze the effect of adding pregabalin or usual care (UC) on 
patient functioning in GAD subjects with partial response (PR) to previous SSRI 
course in daily medical practice. MethOds: Post-hoc analysis of patients with PR 
to SSRI monotherapy enrolled in a prospective 6-month naturalistic study. PR was 
defined as a Clinical Global Impression scale score > 3 and persistence of anxiety 
symptoms > 16 in the Hamilton-Anxiety scale. Two groups (based on psychiatrist 
judgment) were analyzed: adjunctive therapy (AT) with pregabalin (150-600 mg/
day) to existing therapy; or usual care (switching to a different SSRI or adding 
another anxiolytic different than pregabalin). Patient functioning was assessed by 
mean of the disability WHO-DAS-II scale [range 0 (no disability) to 100 (completely 
unable)]. Changes in domains scale scores were compared at end-of-trial visit by 
a general linear model with covariates. Results: Four-hundred-eighty-six newly 
prescribed pregabalin and 239 UC patients [mean (SD) HAM-A 26.7 (6.9) and CGI 4.1 
(0.5)] were analyzed. AT with pregabalin was associated with significantly higher 
mean (95% CI) reductions vs. UC in all the domains of the WHO-DAS-II scale. 
Differences between groups were statistically significant (effect sizes were moder-
ate): understanding and communication [-6.9(-9.8;-4.0), p< 0.001], getting around 
[-5.2(-8.0;-2.8), p< 0.001], self-care [-3.6(-5.5;-1.8), p< 0.001], getting along with oth-
ers [-5.0(-8.6;-1.3), p= 0.007], household [-5.3(-9.6;-1.0), p= 0.015], work activities 
[-6.5(-11.2;-1.8), p= 0.007], and participation in society [-6.3(-9.7;-2.9), p< 0.001]. The 
overall disability score was significantly more reduced in pregabalin group vs. 
UC: -21.7(-23.3;-20.1) vs. -15.3(-17.5;-13.1), p< 0.001. Gender effect was negligible 
(no interaction) in all the dimensions analyzed except household functioning 
(higher reduction in women). cOnclusiOns: In medical practice, GAD patients 
with partial response to prior course of a SSRI experienced greater and meaningful 
functioning improvements with adjunctive therapy with pregabalin in comparison 
with usual care. The effect of pregabalin was independent of patient gender except 
for household functioning.
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Objectives: The effect of mental disorders on absenteeism in Germany has stead-
ily increased. They are now the third-most common reason for sick leave after 
musculoskeletal and respiratory conditions. The aim of this study was to provide 
current estimates of the effect of anxiety and depression on both absenteeism 
and presenteeism in Germany. MethOds: Data from the German respondents 
(N= 15,001) of the 2011 National Health and Wellness Survey were used in the 
analysis. Outcome measures included the Short Form-12v2 (mental and physi-
cal component summary [MCS and PCS] and health utility scores) and the Work 
Productivity and Activity Impairment questionnaire. Respondents who reported 
a diagnosis of anxiety and, separately, a diagnosis of depression were compared 
with respective matched controls (matched on demographic and health his-
tory variables using propensity score matching). Results: A total of 904 (6.0%) 
respondents reported a diagnosis of anxiety (62.6% female, mean age= 44.6 years) 
and 1574 (10.5%) respondents reported a diagnosis of depression (60.2% female; 
mean age= 44.9 years). Compared with matched controls, respondents with anxi-
ety reported significantly greater absenteeism (17.9% vs. 8.1%) and presenteeism 
(36.3% vs. 19.4%) (all p< .05). Similar findings were observed for depression (absen-
teeism: 17%.3 vs. 7.6%; presenteeism: 36.1% vs. 17.1%; all p< .05). These findings 
translated to an incremental 60.7 and 61.1 days lost per year due to absenteeism 
alone for anxiety and depression, respectively. Respondents with anxiety and 
depression also reported significantly lower levels of health status compared 
with matched controls (anxiety: 33.0 vs. 45.7 and 43.5 vs. 46.6 for MCS and PCS, 
respectively, all p< .05; depression: 33.3 vs. 46.6 and 43.8 vs. 47.1 for MCS and PCS, 
respectively, all p< .05). cOnclusiOns: Anxiety and depression were associated 
with significant work impairment along with reduced mental and physical health 
status in Germany. These results suggest greater awareness and early treatment 
could reduce the social and economic burden of these conditions.
